Patents by Inventor Andrew Cansfield
Andrew Cansfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8883820Abstract: The invention relates to compounds of formula (I); wherein X and R1 to R5 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of Itk or PI3K, for the treatment or prophylaxis of immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.Type: GrantFiled: August 30, 2007Date of Patent: November 11, 2014Assignee: Cellzome Ltd.Inventors: Francis Wilson, Nigel Ramsden, Kathryn Bell, Andrew Cansfield, Svenja Burckhardt, Jess Taylor, Mihiro Sunose, David Middlemiss
-
Patent number: 8153389Abstract: The present invention relates to methods for the identification of a PI3K interacting compound using phenylthiazole ligand 1.Type: GrantFiled: August 3, 2007Date of Patent: April 10, 2012Assignee: CellZone AGInventors: Giovanna Bergamini Moore, Andrew Cansfield, Nigel Ramsden, Gitte Neubauer
-
Patent number: 8106236Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: GrantFiled: April 19, 2007Date of Patent: January 31, 2012Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Yan Zhang, Chih Yung Ho
-
Publication number: 20110111972Abstract: The present invention relates to methods wherein a PI3K interacting compound is identified by incubating a PI3K containing protein preparation with phenyl thiazole ligand 1.Type: ApplicationFiled: February 3, 2009Publication date: May 12, 2011Applicant: CELLZOME AGInventors: Andrew Cansfield, Giovanna Bergamini Moore, Gitte Neubauer
-
Patent number: 7825160Abstract: The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: GrantFiled: October 21, 2005Date of Patent: November 2, 2010Assignee: Cellzome LimitedInventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline Leformal, Andrew Cansfield, Svenja Burckhardt
-
Publication number: 20100227800Abstract: The invention relates to compounds of formula (I); wherein X and R1 to R5 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of Itk or PI3K, for the treatment or prophylaxis of immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.Type: ApplicationFiled: August 30, 2007Publication date: September 9, 2010Applicant: CELLZOME LIMITEDInventors: Francis Wilson, Nigel Ramsden, Kathryn Bell, Andrew Cansfield, Svenja Burckhardt, Jess Taylor, Mihiro Sunose, David Middlemiss
-
Publication number: 20100055711Abstract: The present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, c) incubating the phenylthiazole ligand 1-PI3K complex with a given compound, and d) determining whether the compound is able to separate PI3K from the immobilized phenylthiazole ligand 1. Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support and with a given compound under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and c) detecting the phenylthiazole ligand 1-PI3K complex formed in step b).Type: ApplicationFiled: August 3, 2007Publication date: March 4, 2010Inventors: Giovanna Bergamini Moore, Andrew Cansfield, Nigel Ramsden, Gitte Neubauer
-
Patent number: 7557244Abstract: The present invention relates to compounds having the general Formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, and R10 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: GrantFiled: April 20, 2007Date of Patent: July 7, 2009Assignee: Ortho-McNeil Pharmaceutical, Inc.Inventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernadez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Chih Yung Ho, Yan Zhang
-
Publication number: 20090118289Abstract: The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: ApplicationFiled: October 21, 2005Publication date: May 7, 2009Applicant: CELLZOME AGInventors: Francis Wilson, Alison Reid, Valerie Reader, Richard John Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline Leformal, Andrew Cansfield, Svenja Burckhardt
-
Publication number: 20070293567Abstract: The present invention relates to compounds having the general Formula (I) with the definitions of X, Y, R1, R2, R3, R4 R9, and R10 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: ApplicationFiled: April 20, 2007Publication date: December 20, 2007Inventors: Francis WILSON, Alison Reid, Valerie Reader, Richard Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Chih Ho, Yan Zhang
-
Publication number: 20070275961Abstract: Compounds of formula (IA) or (AB) are kinase inhibitors, especially of CDK2, and/or PDK1 and/or CHK1: wherein Ring A is an optionally substituted aryl, heteroaryl, carbocyclic or heterocyclic radical, Alk represents an optionally substituted clivaient C1-C6 alkylene radical; n is 0 or 1; Q represents a radical of formula -(Alk1)p-(X),(Alk2)s-Z wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring, p, r and s are 0 or 1, and Alk1, Alk2, X, are as described in the specification, and R1 represents a radical 3 4 3 (CYC)k-(Alk3)a-(Y)b-(Alk4)d-B wherein k, a, b and d are 0 or 1, and Cyc, Alk3, Alk4 and B are as described in the specification.Type: ApplicationFiled: June 2, 2004Publication date: November 29, 2007Applicant: VERNALIS (CAMBRIDGE) LIMITED.Inventors: Justin Bower, Andrew Cansfield, Allan Jordan, Martin Parratt, Lee Walmsley, Douglas Williamson
-
Publication number: 20070254957Abstract: The present invention relates to compounds having the general formula (I) with the definitions of X, Y, R1, R2, R3, R4, R9, R10 given below, and solvates, hydrates, esters, and pharmaceutically acceptable salts thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of ?-secretase activity.Type: ApplicationFiled: April 19, 2007Publication date: November 1, 2007Inventors: Francis WILSON, Alison Reid, Valerie Reader, Richard Harrison, Mihiro Sunose, Remedios Hernandez-Perni, Jeremy Major, Cyrille Boussard, Kathryn Smelt, Jess Taylor, Adeline LeFormal, Andrew Cansfield, Svenja Burckhardt, Yan Zhang, Chih Ho
-
Publication number: 20070179161Abstract: Compounds of formula (I) or salts, N-oxides, hydrates or solvates thereof are inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent C1-C6 alkylene radical. n is 0 or 1. Q represents a radical of formula -(Alk1)p (X)r-(Alk2)s-Z wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring; Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene radicals which may contain a —O—, —S— or —NRA— link, wherein RA is hydrogen or C1-C6 alkyl; X represents —O—, —S—, —(C?O)—, —(C?S)—, —SO2—, —SO—, —C(?O)O—, —OC(?O)—, —C(?O)NRA—, —NR AC(?O)—, —C(?S)NRA, —NRAC(?S)—, —SO2NRA—, —NRASO2—, —OC(?O)NRA—, —NRAC(?O)O—, or —NRA— wherein RA is hydrogen or C1-C6 alkyl. p, r and s are independently 0 or 1.Type: ApplicationFiled: March 18, 2004Publication date: August 2, 2007Applicant: VERNALIS (CAMBRIDGE) LIMITED.Inventors: Martin Parratt, Justin Bower, Douglas Williamson, Andrew Cansfield